Oppenheimer maintains Outperform rating on Jasper Therapeutics shares By Investing.com
Oppenheimer maintained a positive outlook on Jasper Therapeutics (NASDAQ: JSPR), reiterating an Outperform rating with a firm price target of $80.00.
The company's position comes after evaluating long-term results from a phase 2 study of…